Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

5 Customer Reviews

  • Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cell lines were exposed to the indicated concentrations of carboplatin (A) for 72 hours. Cell viability was assessed by alamarBlue assay and data recorded as fluorescence units at 590 nm. Data are presented as mean μM ± S.E.M. required to inhibit cell viability by 50%, in a minimum of three independent experiments.

    Cancer Lett, 2018, 436:75-86. Carboplatin purchased from Selleck.

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyMVI26oDLzszN NFnOXFM4OiCq MWLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXLvPGZCOjZzM{exNFU>
Tca8113/CBP  MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL4Nk0zPeLCid88US=> NFHEW5I4OiCq NVvncIxUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVfqendyOjZzM{exNFU>
Tca8113/PYM  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyyMVI26oDLzszN NWnWfGpUPzJiaB?= M3XFU4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NUfiUW5HOjZzM{exNFU>
SKOV3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f6blYxKG2pL33s MlLrNU02KGR? NVPtU3BUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= Mn\oNlYyOzdyNEO=
SKOV3 NGH1enJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOUFAuPCEQvHevcYw> MWOyOE81QC95MjDo MXHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NVrlUIlvOjZzMkWyO|M>
SKOV3 NWqwfo1RSXCxcITvd4l{KEG|c3H5 M{HhS|Ih|rypL33s MnPKOFghcA>? MWXpcoR2[2W|IHHwc5B1d3Orcx?= NX;SUGQyOjZzMkWyO|M>
OSA NH3p[oREdG:wb3flcolkKEG|c3H5 NUC3NI9jOi53L{Wg{txO MX;y[ZN2dHS|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51 M1m2XVI3OTFyNkKw
A549 M3PtSGZ2[3Srb36gRZN{[Xl? M1zCVVAwOjVxNUCg{txO NFXsWnEzPCCq MoPi[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= NV\GNYI5OjV7MUezNVc>
H1975 M1:zcmZ2[3Srb36gRZN{[Xl? NH:wS|AxNzJ3L{WwJO69VQ>? NU\ZS2ZJOjRiaB?= MVjkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi M2[yflI2QTF5M{G3
A549 NHvPN2RHfWO2aX;uJGF{e2G7 MlrCNE8zPS93MDFOwG0> NY\XWmxSOjRiaB?= M4LIc5VxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MX[yOVkyPzNzNx?=
H1975 NYXLPZlQTnWldHnvckBCe3OjeR?= MnL6NE8zPS93MDFOwG0> Mnm0NlQhcA>? MWT1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> NEPHVHUzPTlzN{OxOy=>
A549 NVXsUWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKyOUDPxE1? MkjINlQhcA>? MXjpcohq[mm2czDj[YxtKGe{b4f0bC=> NFzpd5ozPTlzN{OxOy=>
H1975 NGOzN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHzVphlOjVizszN M2jEPVI1KGh? NUjXVIZzcW6qaXLpeJMh[2WubDDndo94fGh? M2XrT|I2QTF5M{G3
MDA-MB-231 NITGW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYNE0zOjBizsznM41t NXrKbYtlPzJiaB?= Moj6TWM2OMLiPTC4OkDPxE1? MkTTNlU5Ozd4OUG=
T47D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCwMVIzOCEQvHevcYw> MW[3NkBp NHixNYZKSzVywrC9JFQ5NjlizszN NHXrXFgzPTh|N{[5NS=>
LCTCC NFjOUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LwZmlEPTB;Mz645qCKyrWP M4L4RVI2Pzd|MU[3
MCTCC NVH3OYVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSwfWdRUUN3ME2yMljjiIoEtV2= NFzBWVQzPTd5M{G2Oy=>
MegTCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwMfMAjeK2VQ>? MY[yOVc4OzF4Nx?=
MonoTCC M3nzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vicGlEPTB;NT625qCKyrWP M3XEflI2Pzd|MU[3
MCF7 NWnLNXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yNEDPxE1? NEjWT2Y4OiCq MVHpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> NH7lO|QzPTd4OUCyOS=>
A-549  NXr2flk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL4NE42KM7:TR?= NYHyd21uOjRiaB?= NEf3b5NFVVORwrC= NEW3WXpqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NYfFdFdoOjV5NUW2PVA>
A-549  MYLBdI9xfG:|aYOgRZN{[Xl? NIfiO2IxNjVizszN MVq0PEBp NInQcmRFVVORwrC= Mkjqd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? M2HYV|I2PzV3Nkmw
A-549  NFW2SpNHfWO2aX;uJGF{e2G7 MU[wMlUh|ryP MUG0PEBp MmLDSG1UV8Li M33sWJNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> MoqwNlU4PTV4OUC=
A-549  MmfhSpVkfGmxbjDBd5NigQ>? MlfnNE42KM7:TR?= M2q4SVQ5KGh? MX\EUXNQyqB? M1PjfolvcGmkaYTzJI9nKGOnbHygcYloemG2aX;uxsA> NXjrUGJ7OjV5NUW2PVA>
RMG-1 M2\xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6SFNKSzVyPUK4MlghyrFiMz62JI1oN0x? NXHvZoNZOjV5Mk[5NVM>
FN-RMG-1 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrFbY1KSzVyPUSwMlUhyrFiND6yJI1oN0xMIN88US=> MojaNlU4OjZ7MUO=
RMG-1-hFUT NHfxdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL3d2lEUUN3ME21PE4yKMLzIEKuOEBu\y:O MUSyOVczPjlzMx?=
FN-RMG-1-hFUT MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTv[4VKSzVyPUGxPE45KMLzIEGzMlghdWdxTB?= MX6yOVczPjlzMx?=
CHP-134  M{HRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxJO69VQ>? NHjTWpdFVVORwrC= MXzpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> Ml3NNlU3PTh2NkO=
IMR-32 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yNUDPxE1? M3fmN2ROW00EoB?= NXfpV3hWcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MoLpNlU3PTh2NkO=
CHP-134  NYDXS|FXTnWldHnvckBCe3OjeR?= MlXFNVAh|ryPwrC= MVHEUXNQyqB? NWfXZZF7cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MUGyOVY2QDR4Mx?=
IMR-32 M1;lZWZ2[3Srb36gRZN{[Xl? MUWxNEDPxE4EoB?= NGPBWpBFVVORwrC= M1OzPIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy M2jTd|I2PjV6NE[z
A549 NXLw[YZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\BNE4zNTRyMECg{txO MnfCO|IhcA>? NEjsO|VKSzVyPUGyOkDDuSB3LkCg{txO M{fRN|I2PjJ3MkSz
A549/CDDP MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XuOVAvOi12MECwJO69VQ>? NFXlR5k4OiCq NI\lXJJKSzVyPUK0NOKhyrIEoES1Mlch|ryP NUDsSW5lOjV4MkWyOFM>
H460  MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnWWpVtOjRiaB?= NGnQOXdFVVOR NUK5XYdxUUN3ME23Mlkh|ryP NFrYfFMzPTV7OUm5OS=>
H460  NUTsWIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3Mlkh|ryP NIHkUHIzPCCq NVGwZpZRTE2VTx?= NULBfHZie2ixd4OgZUBz[WSrb4PlcpNqfGm8aX7nJIVn\mWldDD0c{BZNXKjeYO= MWSyOVU6QTl7NR?=
NRK-52E MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS3NuKhcMLi MX\JR|UxRTFyMDFCtUAyOi57IN88US=> NF;CTmozPTV4NU[wNy=>
RGE NIDCWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm1T2k4OsLiaNMg MmKxTWM2OD1{MjFCtUA4NjRizszN MXqyOVU3PTZyMx?=
NRK-52E NVfOSm82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLDO|LDqGkEoB?= MmfpTWM5OD1zN{mgxtEhQS53IN88US=> NUfvcGlxOjV3NkW2NFM>
RGE NWnHXmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrNZo4OsLiaNMg MkDwTWM5OD14MzFCtUA4NjRizszN MYqyOVU3PTZyMx?=
SK-OV-3 NVv6VlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDUZnc4OiCq MkDMTWM2OD1zMESuPEDPxE1? NGDITm8zPTV{MEGzNi=>
ES-2 M{e4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG3NkBp NXHoR2g{UUN3ME2xOE43KM7:TR?= NEPVbFEzPTV{MEGzNi=>
OVCAR-8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73eJI4OiCq MVnJR|UxRTl4LkCg{txO MYqyOVUzODF|Mh?=
3AO NHLXUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp NYDFcllFUUN3ME22N{41KM7:TR?= MlLCNlU2OjBzM{K=
A2780 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzDVYNKPzJiaB?= NX;l[ZBQUUN3ME2xOFUvPyEQvF2= MkjxNlU2OjBzM{K=
SW626 NWnmNI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrmdYs4OiCq NWDN[Y9mUUN3ME25O{4xKM7:TR?= NF;ZS2YzPTV{MEGzNi=>
OVCAR-3 M3\rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp NX:3OGhkUUN3ME2zNk43KM7:TR?= MUKyOVUzODF|Mh?=
A549 NHXze5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? MnrwNlUzPzd2NkG=
4T1 M33PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H1XmlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> NUflcotPOjV{N{e0OlE>
BALB/3T3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOwTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? M2iyW|I2Ojd5NE[x
B16 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTZ2LkOwJOKyKDZwOEGg{txO NGm2c3czPTJ5N{S2NS=>
DU 145 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjrb5V3UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= MlzrNlUzPzd2NkG=
FaDu M3[wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? MkPRNlUzPzd2NkG=
HCV-29T M1zvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fIfmlEPTB;NEiuOVchyrFiMkKuOFkh|ryP MX2yOVI4PzR4MR?=
HL-60 M{nQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;QPFNKSzVyPUGxMlExKMLzIESuOFch|ryP NXzvbJprOjV{N{e0OlE>
HT-29 NH62eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwXYpKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= MnjzNlUzPzd2NkG=
H146 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPlTWM2OD12OT62xtEyOy5zIN88US=> NHu5No4zPTF{NEK4Ni=>
H187 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfvTWM2OD1zMj63xtEzNjdizszN M3z3NFI2OTJ2Mkiy
H128 NXjwZYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPLbnhKSzVyPUGwOk41yrF7Lk[g{txO MUmyOVEzPDJ6Mh?=
H69 NYS1PIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;Xe49KSzVyPUe2MlnDuTJ5Lkig{txO NE\2XVYzPTF{NEK4Ni=>
H209 NGLFUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DqUGlEPTB;MkW4MlHDuTl7Lkig{txO MmLzNlUyOjR{OEK=
DMS153 NHfhTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXaXIV4UUN3ME21O{45yrF7LkKg{txO NXfFe4o4OjVzMkSyPFI>
H526 M2XkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\OTWM2OD15LkNCtVEvPyEQvF2= MXuyOVEzPDJ6Mh?=
DMS114 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\wTWM2OD16NT64xtEyOi56IN88US=> MYmyOVEzPDJ6Mh?=
DMS53 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj3ZY1OUUN3ME2xOFYvOsLzM{[uOEDPxE1? MnTuNlUyOjR{OEK=
HeLa NVjBc5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP1TG9rPS16MDFOwG0> Mo\vbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MnPuNlUyODl|NkC=
MCF-7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[1MVgxKM7:TR?= NWHIXWFzcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4XXc|I2OTB7M{[w
MDA-MB-231 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr0OU05OCEQvF2= MYLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVyyOVExQTN4MB?=
CaOV3 NU\wTJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp NV63[GZNUUN3ME24Ok4yKM7:TR?= M2Lzc|I2ODZ6OES5
OVCAR-3 M3G3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp M1rRbWlEPTB;MUe5MlUh|ryP NXzHUYpnOjVyNki4OFk>
OVCAR-5 NWnWNW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LJRVczKGh? M1LXdWlEPTB;N{WuO{DPxE1? NFnCT2MzPTB4OEi0PS=>
SKOV-3 NUTBSIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[1clczKGh? NImyWJVKSzVyPUWwOEDPxE1? NVzHToZQOjVyNki4OFk>
OVCAR-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILQdGg4OiCq MoLGTWM2OD1{OUCuOkDPxE1? MVGyOVA3QDh2OR?=
OVCAR-8 NFnDRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fFflczKGh? MkjsTWM2OD14OUCuNkDPxE1? M4\IVlI2ODZ6OES5
MA148 NV\kWY03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XjSFI1KGh? MXTJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= M2nmUFI1QDNzMEmx
A549 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL0O3EzPCCq MV3JR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s NF3LWmgzPDh|MUC5NS=>
MDA-MB-231 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLGd5FFOjRiaB?= NFO2N3hKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t NHzuS3QzPDh|MUC5NS=>
NCI-ADR/RES  NWXYNFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMWZIzPCCq MVzJR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> MV2yOFg{OTB7MR?=
MA148 M3PnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv3SIc1QCCq MWHJR|UxRTJ6LkJihKnDueLCiUGuNEDPxGdxbXy= NWm4dlhwOjR6M{GwPVE>
A549 M3nENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LLdFQ5KGh? M4rCPGlEPTB;MUG4MlDjiIoEsfMAjVEvOiEQvHevcYw> M163cFI1QDNzMEmx
MDA-MB-231 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfTRnpDPDhiaB?= MlLBTWM2OD1zOEOuNQKBkcLz4pEJNU4zKCEQvHevcYw> NVPOOoR3OjR6M{GwPVE>
NCI-ADR/RES  NHPjfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS0PEBp NIXL[JVKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t NYjuS3NkOjR6M{GwPVE>
MA148 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp M375PWlEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=> MVqyOFg{OTB7MR?=
A549 M2f4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfUdmFpPzJiaB?= MUfJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= NEXndFIzPDh|MUC5NS=>
MDA-MB-231 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETHfZk4OiCq NWPLSIFTUUN3ME25PU426oDLwsJihKkyNjFizsznM41t NHOz[o0zPDh|MUC5NS=>
NCI-ADR/RES  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDUFczKGh? M1rZfWlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> NUnRfVMxOjR6M{GwPVE>
A549 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P2TlczKGh? MV7EUXNQ NIPpVndKSzVyPUG1Nk41ODlizszN M3KwW|I1PzJzM{Kz
NCI-H157 NXHvdnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp NEnFOphFVVOR NEL3WGtKSzVyPUi5Mlk4PyEQvF2= M4LQ[|I1PzJzM{Kz
PC9 M2j2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPSd5c4OiCq M17mcGdEPTB;N{GuOuKyQS53INM1US=> NGLpN5ozPDZzOEiwPS=>
A549  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LM[lczKGh? M2HIbWdEPTB;MUO2xtE{OS54INM1UeKh MUGyOFYyQDhyOR?=
PC9 MVrBdI9xfG:|aYOgRZN{[Xl? NIL6WXIyODBiwsXN MknWO|IhcA>? MlTTbY5lfWOnczDhdI9xfG:|aYO= M3LTTVI1PjF6OEC5
A549  M37mXWFxd3C2b4Ppd{BCe3OjeR?= NVT5bGcxOTByINM1US=> NILTTXM4OiCq MYDpcoR2[2W|IHHwc5B1d3Orcx?= M2Pn[VI1PjF6OEC5
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuyO|IzPCCq NXzUdnNVUUNzME2xMlQ4PiCwTR?= MWCyOFM6PjR|Nx?=
H1299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH6R|AzPCCq MXHJR|ExRTBwNESzJI5O MlrFNlQ{QTZ2M{e=
HCC15 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[4NlQhcA>? MULJR|ExRTBwM{S2JI5O NF\jOYMzPDN7NkSzOy=>
H157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvOlEzPCCq Mm\ZTWMyOD1yLkixJI5O NV\HOVl6OjR|OU[0N|c>
A2780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? NITCSGozPDJyOU[5Ny=>
A2780cisR NIPPZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR6LkpihKnDueLCiUOuPUDPxE1? NGjoWmczPDJyOU[5Ny=>
A2780ZD0473R NFK1OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXrdJBtUUN3ME22OE436oDLwsJihKk{NjJizszN Mn7ONlQzODl4OUO=
SKOV-3 NFjGUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR|LkVihKnDueLCiUOuPUDPxE1? MVSyOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID